Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + durvalumab + capecitabine conversion therapy for locally advanced or metastatic biliary tract cancer
ChiCTR2300073741Phase 2Not yet recruiting
- Sponsor
- Shanghai Xuhui District Central Hospital
- Start
- Aug 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, durvalumab and capecitabine in biliary cancer, sponsored by Shanghai Xuhui District Central Hospital. Primary endpoint: Pathological complete response rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
surufatinibdurvalumabcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2300073741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073741.